viewNemaura Medical Inc

Nemaura Medical announces closing of $2 million offering

The company plans to use part of the funds toward an FDA-approved clinical trial

Sugar cubes with heart shape
Nemaura Medical is a medical technology company focusing on diabetes management

Nemaura Medical Inc (NASDAQ:NMRD) announced the closing of a public offering that grossed around $2 million.

In a Thursday statement, it said the offering of 1,942,061 units consisted of one common share sold at $1.04 per share. That represented a 25% discount to the market price of $1.39 in September at the time of the deal's announcement.

There is also a series of 1,942,061 60-Month Warrants at 100% coverage with an exercise price of $1.04.

Dawson James Securities Inc acted as the sole placement agent on the transaction.   

BIG PICTURE: Nemaura is a red-hot medtech stock with a winner in its painless sugarBEAT glucose monitor

Nemaura Medical plans to use the net proceeds from the offering towards an FDA clinical trial, a product launch in Europe and the development of a second generation of sugarBEAT, which is a needle-free, non-invasive continuous glucose measurement for better diabetes and lifestyle management.

Nemaura Medical is a medical technology company that discovers, develops, and commercializes specialty medical devices. The company also helps people with diabetes and pre-diabetics to better manage their glucose levels.

Contact Rene Pastor by [email protected]

Quick facts: Nemaura Medical Inc

Price: 3.7 USD

Market: NASDAQ
Market Cap: $84.76 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...


Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read